Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Martin

Showing results (311-320 of 361) with videos related to

Pageof 37
Sort By:
Cancer|July 17, 2015
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myelomaJohanna C Bendell, Robin K Kelley, Kent C Shih, et al.
Blood Cancer Journal|September 26, 2023
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
The Lancet. Haematology|July 27, 2024
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trialKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.
Journal of Hematology & Oncology|August 18, 2021
Making clinical decisions based on measurable residual disease improves the outcome in multiple myelomaJoaquin Martinez-Lopez, Rafael Alonso, Sandy W Wong, et al.
Bioconjugate Chemistry|September 3, 2015
Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition ChemistryMichael P VanBrunt, Kurt Shanebeck, Zachary Caldwell, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2009
The delineation of target volumes for radiotherapy of lung cancer patientsHilke Vorwerk, Gabriele Beckmann, Michael Bremer, et al.
Expert Opinion on Investigational Drugs|July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsPaul G Richardson, Elisabeth K O'Donnell, Peter O'Gorman, et al.
Blood|February 27, 2026
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ studyRobert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living GuidelineLisa K Hicks, Hans J Messersmith, Samer Al Hadidi, et al.
Haematologica|December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceMaria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Pageof 37

Showing results (311-320 of 361) with videos related to

Sort By:
Pageof 37
Cancer|July 17, 2015
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myelomaJohanna C Bendell, Robin K Kelley, Kent C Shih, et al.
Blood Cancer Journal|September 26, 2023
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
The Lancet. Haematology|July 27, 2024
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trialKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.
Journal of Hematology & Oncology|August 18, 2021
Making clinical decisions based on measurable residual disease improves the outcome in multiple myelomaJoaquin Martinez-Lopez, Rafael Alonso, Sandy W Wong, et al.
Bioconjugate Chemistry|September 3, 2015
Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition ChemistryMichael P VanBrunt, Kurt Shanebeck, Zachary Caldwell, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2009
The delineation of target volumes for radiotherapy of lung cancer patientsHilke Vorwerk, Gabriele Beckmann, Michael Bremer, et al.
Expert Opinion on Investigational Drugs|July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsPaul G Richardson, Elisabeth K O'Donnell, Peter O'Gorman, et al.
Blood|February 27, 2026
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ studyRobert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living GuidelineLisa K Hicks, Hans J Messersmith, Samer Al Hadidi, et al.
Haematologica|December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceMaria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Pageof 37